Intelgenx Technologies Corp
TSX:IGX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Intelgenx Technologies Corp
Short-Term Debt
Intelgenx Technologies Corp
Short-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Short-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Intelgenx Technologies Corp
TSX:IGX
|
Short-Term Debt
$10.7m
|
CAGR 3-Years
45%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Canopy Growth Corp
TSX:WEED
|
Short-Term Debt
CA$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cronos Group Inc
TSX:CRON
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Short-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Short-Term Debt
CA$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Intelgenx Technologies Corp
Glance View
IntelGenx Technologies Corp. is a oral drug delivery company, which focuses on the development and manufacturing of pharmaceutical oral films based on its proprietary VersaFilm technology platform. The company is headquartered in Saint-Laurent, Quebec. The company went IPO on 2008-05-23. The firm is focused on the development and manufacturing of pharmaceutical films. The firm's pharmaceutical film technologies include VersaFilm, DisinteQ, VetaFilm and transdermal VevaDerm, which allows pharmaceutical products that address unmet medical needs. The firm's product pipeline offers various benefits to patients and physicians for many therapeutic conditions. Its VersaFilm research and development (R&D) services are based on a versatile drug delivery platform technology that enables the development of oral thin films exhibiting improved product performance. Its VetaFilm R&D services and veterinary oral films provide various market opportunities for improved drug delivery for companion animals. Its product portfolio includes RIZAPORT (Rizatriptan), EXORDIA (Tadalafil), Loxapine, Montelukast, Buprenorphine / Naloxone, and Dronabinol AdVersa (Dronabinol).
See Also
What is Intelgenx Technologies Corp's Short-Term Debt?
Short-Term Debt
10.7m
USD
Based on the financial report for Mar 31, 2024, Intelgenx Technologies Corp's Short-Term Debt amounts to 10.7m USD.
What is Intelgenx Technologies Corp's Short-Term Debt growth rate?
Short-Term Debt CAGR 3Y
45%
The average annual Short-Term Debt growth rates for Intelgenx Technologies Corp have been 45% over the past three years .
